JRVR vs TRDA Comparison

James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.